Skip to main content

Vir Biotechnology Inc

For the period ended Dec 31, 2024. Filed Feb 27, 2025.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Feb 27, 2025

VIR$13.65+11.8%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Signature

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

VIR BIOTECHNOLOGY, INC.
Date: February 26, 2025By:/s/ Marianne De Backer
Marianne De Backer, M.Sc., Ph.D., MBA
Chief Executive Officer and Director
(Principal Executive Officer)
Date: February 26, 2025By:/s/ Jason O’Byrne
Jason O’Byrne, MBA
Executive Vice President and Chief Financial Officer
(Principal Financial Officer)

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Marianne De Backer, M.Sc., Ph.D., MBA, Jason O’Byrne, MBA, and Vanina de Verneuil, J.D., and each of them, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution for him or her and in his or her name, place, and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with exhibits thereto and other documents in connection therewith, with the SEC, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, and any of them or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.

SignatureTitleDate
/s/ Marianne De BackerChief Executive Officer and DirectorFebruary 26, 2025
Marianne De Backer, M.Sc., Ph.D., MBA(Principal Executive Officer)
/s/ Jason O’ByrneExecutive Vice President and Chief Financial Officer(Principal Financial Officer)February 26, 2025
Jason O’Byrne, MBA
/s/ Brent SabatiniSenior Vice President and Chief Accounting Officer(Principal Accounting Officer)February 26, 2025
Brent Sabatini, CPA, MBA
/s/ Vicki SatoChairman of the Board of DirectorsFebruary 26, 2025
Vicki Sato, Ph.D.
/s/ Norbert BischofbergerDirectorFebruary 26, 2025
Norbert Bischofberger, Ph.D.
/s/ Ramy FaridDirectorFebruary 26, 2025
Ramy Farid, Ph.D.
/s/ Jeffrey S. HatfieldDirectorFebruary 26, 2025
Jeffrey S. Hatfield
/s/ Robert MoreDirectorFebruary 26, 2025
Robert More
/s/ Janet NapolitanoDirectorFebruary 26, 2025
Janet Napolitano
/s/ Robert NelsenDirectorFebruary 26, 2025
Robert Nelsen
/s/ Saira RamasastryDirectorFebruary 26, 2025
Saira Ramasastry
/s/ George ScangosDirectorFebruary 26, 2025
George Scangos, Ph.D.
/s/ Elliott SigalDirectorFebruary 26, 2025
Elliott Sigal, M.D., Ph.D.
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.